病毒性肝炎的广泛流行，导致我国肝硬化的患病率和死亡率长期居高不下。肝纤维化是各种慢性肝病发展至肝硬化的必经病理过程，具有可逆性，因此治疗肝纤维化，减缓、阻止乃至逆转其病理进程，已成为治疗肝硬化的重要手段。但目前临床上没有一种可靠有效的治疗肝纤维的治疗手段。而吡非尼酮是一种新的抗纤维化、抗炎药物，已经应用于特发性肺纤维的临床治疗中。同时本课题组的前期研究也发现，吡非尼酮可有效地降低胶原I的合成。据此，我们充分利用吡非尼酮的抗纤维化及抗炎作用，经门静脉注入于肝脏，阻断胶原合成，减缓、阻止乃至逆转肝纤维化。本项目的意义在于为肝纤维化的治疗，寻找新的治疗手段，有望为肝硬化的治疗策略提供新的思路，因此具有较大的理论研究意义和潜在的应用价值。

In China, the morbidity and mortality of cirrhosis are always high due to prevalent virus hepatitis. Cirrhosis results from different mechanisms of liver injury that lead to liver fibrosis ,which is is reversible. Then researchers have been stimulated to identify antifibrotic therapies. Pirfenidone (PFD) is a novel anti-fibrotic and anti-inflammatory agent that inhibits the progression of fibrosis, and it has been widely used as an oral formulation for systemic treatment of idiopathic pulmonary fibrosis. Our previous research has also shown that PFD can prevent the proliferation and activation of cultured HSC and reduce the synthesis of collagen I. In the present study, pirfenidone is to be perfused.to the liver via the portal vein. This method will block collagen secretion,degrade ECM and even reverse fibrosis. This study would provide new.insight into the mechanism of liver fibrosis and novel treatment for cirrhosis.